Table 1.
Demographic and clinical characteristics of the CIS, RRMS and SPMS patients.
| Variables | CIS patients (n1 = 6) | RRMS patients (n2 = 67) | SPMS patients (n3 = 9) | p-value |
|---|---|---|---|---|
| Age (years), mean ± SD | 33.0 ± 7.8 | 43.4 ± 10.2 | 51.6 ± 9.2 | 0.003* |
| Gender, n (%) | 0.0003* | |||
| Male | 4 (66.7) | 10 (14.9) | 6 (66.7) | |
| Female | 2 (33.3) | 57 (85.1) | 3 (33.3) | |
| Age at disease onset (years), median [IQR] | 28 [27; 30.5] | 28 [23.5; 39.5] | 34 [32.0; 41.0] | 0.528 |
| Duration of disease (years), median [IQR] | 2 [1.25; 2.75] | 10 [7.5; 15.5] | 13 [11.0; 24.0] | 0.001* |
| Lesion location on MRI | 0.874 | |||
| Supratentorial or infratentorial region | 2 (33.3) | 14 (20.9) | 4 (44.4) | |
| Both regions | 1 (16.7) | 23 (34.3) | 2 (22.2) | |
| supratentorial + infratentorial + MS | 2 (33.3) | 21 (31.3) | 2 (22.2) | |
| supratentorial + MS | 1 (16.7) | 9 (13.4) | 1 (11.1) | |
| EDSS Score at admission | 0 [0, 0.75] | 2 [1; 3] | 6 [4; 6.5] | <0.0001* |
| Disease-modifying treatment, n (%) | 0.479 | |||
| Interferon-beta | 2 (33.3) | 33 (49.3) | 6 (66.7) | |
| Glatiramer acetate | 4 (66.7) | 34 (50.7) | 3 (33.3) | |
| Duration of disease-modifying treatment (months), median [IQR] | 16 [8.3; 24.5] | 72 [30.0; 120.0] | 156 [132.0; 156.0] | 0.001* |
CIS-clinically isolated syndrome; RRMS-relapsing remitting multiple sclerosis; SPMS-secondary progressive multiple sclerosis; MRI-magnetic resonance imaging; MS- multiple sclerosis; SD = standard deviation; IQR = [Q1, Q3] where Q1 = Quartile1; Q3 = Quartile 3; n (%) = absolute frequencies (% percentages estimated from the size of group); p-values obtained from ANOVA, Kruskal-Wallis test or Fisher's exact test; * significant results: p-value <0.05.